小剂量利妥昔单抗治疗造血干细胞移植后EBV感染的疗效分析  

Analysis on the efficacy of low-dose rituximab in the treatment of EBV infection after hematopoietic stem cell transplantation

作　　者：张晓瀚[1] 蔡云[1] 汪鹏程[1] 范憬超 陈诗彧 杜新[1] ZHANG Xiaohan;CAI Yun;WANG Pengcheng;FAN Jingchao;CHEN Shiyu;DU Xin(Department of Hematology,the Second People’s Hospital of Shenzhen,Guangdong,Shenzhen 518035,China)

机构地区：[1]深圳市第二人民医院血液内科,广东深圳518035

出　　处：《中国医药科学》2022年第2期24-28,共5页China Medicine And Pharmacy

摘　　要：目的应用小剂量利妥昔单抗治疗异基因造血干细胞移植(allo-HSCT)后EBV感染的疗效分析。方法回顾分析深圳市第二人民医院2018年1月至2020年12月38例allo-HSCT后应用小剂量利妥昔单抗治疗EBV感染的疗效并复习相关文献。结果本研究共纳入研究病例38例,其中35例(92.11%)完全缓解(CR),3例(7.89%)部分缓解(PR),无患者病情进展为EBV-PTLD。主要不良反应:6例(15.7%)患者出现寒战,5例(13.2%)患者出现发热,2例(5.3%)患者出现胸闷,在给予对症治疗后均缓解,缓解后能够继续完成治疗。结论小剂量利妥昔单抗在早期EBV感染的治疗中取得了较好效果,输注相关的不良反应发生较少,治疗耐受性好。Objective To analyze the efficacy of low-dose rituximab in the treatment of Epstein-Barr virus(EBV)infection after allogeneic hematopoietic stem cell transplantation(allo-HSCT).Methods The efficacy of low-dose rituximab for 38 patients with EBV infection after allo-HSCT admitted to the Second People’s Hospital of Shenzhen from January 2018 to December 2020 was retrospectively analyzed and the related pieces of literature were reviewed.Results A total of 38 patients were included in this study,including 35 patients(92.11%)with complete response(CR),and 3 patients(7.89%)with partial response(PR),and no patient progressed to EBV-induced post transplant lymphoproliferative disorder(EBV-PTLD).The main adverse reactions were chills in 6 patients(15.7%),fever in 5 patients(13.2%)and chest tightness in 2 patients(5.3%).All of these adverse reactions were relieved after being treated symptomatically,which enabled patients to complete the treatment.Conclusion Low-dose rituximab is effective in the treatment of early EBV infection,with fewer infusion-related adverse reactions and good treatment tolerability.

关 键 词：异基因造血干细胞移植 EBV感染 利妥昔单抗 小剂量 

分 类 号：R614[医药卫生—麻醉学]